Cash used in operations during the year ended Decemwas $51.0 million compared to $45.1 million for the twelve months ended December 31, 2021. Operating loss for the twelve months ended Decemwas $57.6 million compared to $56.7 million for the twelve months ended December 31, 2021. UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the first quarter of 2024.
Tie2/VEGF bispecific preclinical data to support selection of development candidate expected by end of 2023įourth Quarter and Full Year Financial ResultsĬash, cash equivalents and marketable securities totaled $94.8 million as of Decemcompared with $90.1 million as of December 31, 2021. UBX1325 48-week safety and efficacy data from the Phase 2 BEHOLD DME study expected in the second quarter of 2023. 
UBX1325 16- and 24-week safety and efficacy data from the Phase 2 ENVISION wet AMD study expected by end of March 2023. As we prepare for our 24-week readout of the ENVISION study later this month, I am grateful for the strong support from our physician and patient community who share our excitement for UBX1325, its novel mechanism of action, and the potential benefit in vision and the durability of treatment.” “And third, we completed enrollment in our Phase 2 ENVISION study for patients with age-related macular degeneration. Second, we completed an important and upsized financing to accelerate value generation in our clinical development of UBX1325,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “In 2022, we achieved three key goals that set us up for a transformative 2023: First, we achieved positive 24-week data from our Phase 2 BEHOLD study in UBX1325 in patients with diabetic macular edema, a ground-breaking clinical proof-of-concept for our novel senolytic small molecule and for the senescence biology and anti-aging field. (UNITY), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2022. SOUTH SAN FRANCISCO, Calif., Ma(GLOBE NEWSWIRE) - UNITY Biotechnology, Inc.
0 kommentar(er)
